Brief: Rallybio Announces Proof-Of-Concept Results And Development Updates For Rlyb212, A Novel Monoclonal Anti-HPA-1A Antibody

Rallybio

24/06/2023 20:32

June 24 (Reuters) - Rallybio Corp  RLYB.O :
    * ANNOUNCES PROOF-OF-CONCEPT RESULTS AND DEVELOPMENT UPDATES
FOR
RLYB212, A NOVEL MONOCLONAL ANTI-HPA-1A ANTIBODY TO PREVENT
FETAL AND NEONATAL ALLOIMMUNE THROMBOCYTOPENIA
    * RLYB212 DEMONSTRATED DOSE-DEPENDENT, RAPID AND COMPLETE
ELIMINATION OF TRANSFUSED HPA-1A POSITIVE PLATELETS IN HPA-1A
NEGATIVE SUBJECTS
    * MEAN REDUCTION IN PLATELET ELIMINATION HALF-LIFE AFTER
ADMINISTRATION WAS ≥90% IN BOTH RLYB212 DOSE GROUPS, ACHIEVING
PROOF-OF-CONCEPT CRITERIA
    * PHASE 2 STUDY IN PREGNANT WOMEN AT HIGHER RISK OF HPA-1A
ALLOIMMUNIZATION TO BE INITIATED IN 2H 2024
    * PHASE 1 MULTIPLE DOSE DATA AND MATERNAL-FETAL TOXICOLOGY
DATA
ON-TRACK FOR 4Q 2023-

Source text for Eikon:  ID:nBw8ry8tya 
Further company coverage:  RLYB.O 

 ((Reuters.Briefs@thomsonreuters.com;))